StockData
Candel Therapeutics, Inc. logo

Candel Therapeutics, Inc. (CADL) stock

CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 1/30
$5.32−0.08 (-1.48%)

Close on Nov 18, 2026Market cap $407.08MP/E –Yield –

Candel Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Candel Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$71.99M. For fiscal 2025 it was -$48.27M. The highest annual figure on record is -$13.81M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$48.27M–
FY2024Dec 31, 2024-$33.37M–
FY2023Dec 31, 2023-$38.39M–
FY2022Dec 31, 2022-$34.72M–
FY2021Dec 31, 2021-$25.73M–
FY2020Dec 31, 2020-$13.81M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$26.75M–
Q1 FY2026Mar 31, 2026-$16.28M–
Q4 FY2025Dec 31, 2025-$15.75M–
Q3 FY2025Sep 30, 2025-$13.21M–
Q2 FY2025Jun 30, 2025-$11.18M–
Q1 FY2025Mar 31, 2025-$8.13M–
Q4 FY2024Dec 31, 2024-$8.14M–
Q3 FY2024Sep 30, 2024-$8.76M–
Q2 FY2024Jun 30, 2024-$8.57M–
Q1 FY2024Mar 31, 2024-$7.90M–
Q4 FY2023Dec 31, 2023-$10.32M–
Q3 FY2023Sep 30, 2023-$8.86M–
Q2 FY2023Jun 30, 2023-$9.58M–
Q1 FY2023Mar 31, 2023-$9.63M–
Q4 FY2022Dec 31, 2022-$8.10M–
Q3 FY2022Sep 30, 2022-$8.88M–
Q2 FY2022Jun 30, 2022-$8.75M–
Q1 FY2022Mar 31, 2022-$8.99M–
Q4 FY2021Dec 31, 2021-$7.74M–
Q3 FY2021Sep 30, 2021-$8.03M–
Q2 FY2021Jun 30, 2021-$5.30M–
Q1 FY2021Mar 31, 2021-$4.66M–
Q4 FY2020Dec 31, 2020-$6.13M–
Q3 FY2020Sep 30, 2020-$2.75M–
Q2 FY2020Jun 30, 2020-$2.62M–

More Candel Therapeutics figures

See a number that looks wrong?